louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00000300: Feasibility Study of Take-Home LAAM Medication - 3
Official title: Feasibility Study of Take-Home LAAM Medication
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Opioid-Related Disorders
Keywords: opiate
dependence
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used; (3) Does treatment response correlate with background or drug use variables at intake, discharge, or during treatment?

Detailed description: 1-Year study, participant will be randomly assigned to one of two groups: One will have the opportunity to earn take-home doses by turning in a designated number of clean urines. Two will not have the opportunity to earn take-home doses. Clinic visits three times per week. Urine sample given at each visit.

Eligibility criteria: Inclusion Criteria:

meets DSM-IV criteria for opiate dependence. M/F, 18 years or older. Certified for LAAm treatment by a physician. Able to understand english. Willing to provide names, addresses, and numbers of 3 relatives who can aid in patient location for follow-up visits.

Exclusion Criteria:

Hypertensive to LAAM. Pregnant or nursing women. Female of childbearing potential who refuses to use an acceptable form of birth control. Clinically significant abnormality in hematology, blood work, or UA, ETOH and/or sedative/hypnotic dependence according to DSM-IV criteria. Medical or psychiatric illness which would jeopardize safe study participation.

Primary outcomes:
measure: Drug use
measure: Retention
measure: Increased prosocial behaviors
measure: Decreased frequency of HIV related behavior
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Friends Research Institute
state: California
Study officials:
affiliation: Friends Research Institute, Inc.
name: Walter Ling, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06372600: Effect of Extracorporeal Shock Wave Combined With Autologous Platelet-rich Plasma Injection on Rotator Cuff Calcific Tendinitis
Official title: Effect of Extracorporeal Shock Wave Combined With Autologous Platelet-rich Plasma Injection on Rotator Cuff Calcific Tendinitis: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Rotator Cuff Tendinitis
Rotator Cuff Tendinosis
Keywords: Rotator cuff calcifying tendinitis
PRP
ESW
Lead sponsor: Chengdu Sport University
Sponsor class: OTHER
First posted: 2024-04-18
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to explore the effect of extracorporeal shock wave combined with autologous platelet-rich plasma injection on the rehabilitation of rotator cuff calcific tendinitis, to provide new treatment methods and evidence for the rehabilitation of rotator cuff calcific tendinitis, and to reduce patients; pain and return to normal life as soon as possible.

Detailed description: The purpose of this study is to explore the effect of extracorporeal shock wave combined with autologous platelet-rich plasma injection on the rehabilitation of rotator cuff calcific tendinitis, to provide new treatment methods and evidence for the rehabilitation of rotator cuff calcific tendinitis, and to reduce patients\&#39; pain and return to normal life as soon as possible.

Eligibility criteria: Inclusion Criteria:

* Meet the diagnostic criteria for rotator cuff calcific tendonitis, aged between 40 and 60 years old
* Persistent pain in the affected shoulder, with obvious tenderness under the acromion and rotator cuff, as confirmed by X-ray and Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) examination showed one or more round-shaped high-density calcium salt deposits near the greater tuberosity of the humerus
* All were diagnosed for the first time
* Complaints of severe pain in the shoulder joint, obvious

Exclusion Criteria:

* Combined with rotator cuff trauma, long head of biceps tendonitis and other shoulder joint diseases
* Past combined history of shoulder joint surgery
* Patients with internal fixation of the shoulder joint
* Shoulder joint combined with infection, Tumors and other lesions
* Combined with severe heart, liver, and kidney dysfunction
* Do not agree to participate in the study or fail to sign the informed consent form.

Primary outcomes:
measure: Visual Analogue Scale,VAS
timeFrame: After 1, 2, 4 and 8 weeks of intervention
Secondary outcomes:
measure: American Shoulder and Elbow Surgeon's Form,ASES
timeFrame: After 1, 2, 4 and 8 weeks of intervention
measure: the university of California at Los Angeles shoulder rating scale, UCLA
timeFrame: After 1, 2, 4 and 8 weeks of intervention
measure: The location and size of the calcifications were examined by ultrasound
timeFrame: After 4 and 8 weeks of intervention
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03586700: Based on the Ultrasound Evaluating the Effect of Xiaozhong Fang Particles for Knee Osteoarthritic With Synovial Fluid
Official title: Based on the Ultrasound Evaluating the Effect of Xiaozhong Fang Particles for Knee Osteoarthritic With Synovial Fluid
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Knee Osteoarthritis
Keywords: Knee Osteoarthritis
Synovium effusion
RCT
placebo
Lead sponsor: Beijing University of Chinese Medicine
Sponsor class: OTHER
First posted: 2018-07-16
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a randomized, single blind, controlled trial. Aim to compare the effectiveness (especially the absorption degree of the synovial effusion measured by B ultrasonic) of the treatment group with the control group. The treatment group was given Xiao zhong fang granules orally and short wave infrared radiation and the control group was given the placebo Xiao zhong fang granules orally and short wave infrared radiation. To evaluate the clinical efficacy of the Chinese medicine in the treatment of the synovial effusion of knee osteoarthritis.


Eligibility criteria: Inclusion Criteria:

* 1) the American Society of Rheumatology established the diagnostic criteria for knee OA in 2001;
* 2) Kellgren/Lawrence score of knee joint grade as I,II and early III.
* 3) According to "Principles of clinical guidance for new drugs of traditional Chinese Medicine ",diagnosed as "Xi Bi Disease".
* 4) Patients with informed consent.
* 5)Blood and urine routine tests, liver and kidney functions, electrocardiogram were normal before recruitment.
* 6) Patients were not treated with NSAIDS drugs or hormone drugs, and no patients were treated with drugs related to this disease at least 2 weeks.

Exclusion Criteria:

* 1)Patients suffer from other rheumatic and metabolic diseases such as gout, rheumatoid arthritis, diabetes and so on.
* 2) Patients with knee joint inflammatory infection, such as suppurative and nonspecific.
* 3)Patients accompanied by traumatic synovitis, Villonodular pigmented synovitis, synovial membrane of the knee is the main lesion.
* 4) Patients with informed consent.
* 5)The color of joint fluid of patients' knees is pink or other color or cloudy; the white blood cell counts \> 1000 /mm3 or with crystal in the joint fluid.
* 6)Patients blood RF \> 30IU/ml, ESR \> 20mm/h, CRP \> 10mg/L.
* 7)Patients combined with severe cardiovascular, cerebrovascular, liver, kidney and other primary diseases and mental diseases.

Primary outcomes:
measure: Walther grading of synovial effusion of Knee joint
timeFrame: After treatment(28days)
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Dongzhimen Hospital Beijing University of Chinese Medicine
state: Bejiing
Study officials:
affiliation: Dongzhimen Hospital, Beijing
name: DUODUO LI, MASTER
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02743000: Food and the Brain
Official title: Emotion and Reward Processing in Binge Eating
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Binge Eating
Keywords: fMRI
emotion conflict task
monetary incentive delay
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2016-04-19
Enrollment: 83
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women ages 18-35

Brief summary: The proposed study will examine the role of reward and emotion in women with and without a history of binge eating. It is important to understand how the brain responds to reward and emotion in binge eating in order to identify different pathways toward binge eating and provide individualized targets for treatment. This is particularly important in light of the fact that for many patients, the current treatments for binge eating are not effective.


Eligibility criteria: Inclusion Criteria:

* Female
* Ages 18-35
* with or without current binge eating behaviors

Exclusion Criteria:

* Any contraindication for MRI (orthodontia, vascular stents, metallic ear tubes, metal implants, piercings, etc).
* substance abuse
* traumatic brain injury
* BMI \< 18.5
* pregnant women

Primary outcomes:
measure: Brain activity during rest
timeFrame: Baseline
measure: Brain activity during emotion conflict
timeFrame: Baseline
measure: Brain activity during monetary wins and losses
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University, Department of Psychiatry
state: California
Study officials:
affiliation: Stanford University
name: Cara Bohon, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02405000: Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance
Official title: Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oropharyngeal Cancer
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
First posted: 2015-04-01
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The objective of this research is to perform a pilot study on patients undergoing laryngoscopy for diagnostic and tumor staging purposes (for pharyngeal or laryngeal cancer) in which intraoperative CT imaging will be performed both prior to (but after induction of general endotracheal anesthesia) and during placement of the laryngoscope in order to better understand anatomic changes that occur during instrumentation of the oral cavity and oropharynx. The goals of the study are:

1. Develop a suite of de-identified images and surface renderings that qualitatively show how a tumor and the upper aerodigestive tract anatomy deform during a laryngoscopic evaluation.
2. Create deformation models of the upper aerodigestive tract.

This data to be used for future retractor development as well as for virtual image guided surgery.


Eligibility criteria: Inclusion Criteria:

* Adult patients (\>18 years) seen in the Head and Neck Tumor Clinic who will require laryngoscopy in the operating room for diagnosis and staging of known or suspected tumors of the upper aerodigestive tract.

Exclusion Criteria:

* Patients who are unable to tolerate general anesthesia.
* Patients who are felt to be a "difficult airway" for induction of general endotracheal anesthesia.
* Patients with excessive dental restorations and amalgam.

Primary outcomes:
measure: Radiographic evidence of upper aerodigestive tract deformation during laryngoscopy
timeFrame: Collected at the time of surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center
state: New Hampshire
Study officials:
affiliation: Dartmouth-Hitchcock Medical Center
name: Joseph A Paydarfar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03196700: Short Course Radiation Therapy in Palliative Treatment
Official title: Short Course Accelerated Radiation Therapy in Palliative Treatment of Advanced Head and Neck Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palliative Care
Keywords: palliative care
head and neck cancer
radiotherapy
pain
quality of life
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2017-06-23
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study wants to define the maximum tolerated dose (MTD), safety and efficacy of a short course radiation treatment in patients with symptomatic advanced head and neck cancer.

Detailed description: The study wants to define the maximum tolerated dose (MTD) of a conformal short course accelerated radiation therapy delivered in twice daily fractions and 2 consecutive days, and the feasibility of this fractionation in term of safety and efficacy for symptomatic palliation of metastatic or locally advanced head and neck cancer.

Eligibility criteria: Inclusion Criteria:

* histologically proven locally advanced or metastatic H\&N cancer
* excluded from curative therapy because of disease stage and/or presence of multiple comorbidities and/or poor performance status
* age \> 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status \< 3

Exclusion Criteria:

* prior RT to the same region.

Primary outcomes:
measure: Maximum tolerated dose
timeFrame: 1 year
Secondary outcomes:
measure: Acute toxicity
timeFrame: 1 year
measure: Quality of life
timeFrame: 1 year
measure: Pain relief
timeFrame: 1 year
measure: Late toxicity
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
name: Alessio G. Morganti, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01970800: The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature
Official title: The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Short Stature
Keywords: IGF-1
Short Stature
GH
Lead sponsor: Maimonides Medical Center
Sponsor class: OTHER
First posted: 2013-10-28
Enrollment: 0
Sex: ALL
Minimum age (years): 5
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This study was changed to a retrospective chart review. There was no prospective component.
Primary purpose: OTHER

Brief summary: The purpose of the study is to evaluate the predictive value of IGF-1 generation test for growth velocity during GH treatment for 12 months.


Eligibility criteria: Inclusion Criteria:

* ability to provide written informed consent
* Prepubertal males and females form 5- 11years old
* Bone age \<11 years in males and \<9 years in females
* Height SD score\<-2.25SD in males and females
* IGF-1SD score \<-1SD in both males and females
* Peak GH level after stimulation \>10ng/ml

Exclusion Criteria:

* History of prior chemotherapy and or radiation
* Active neoplasm
* Pediatric patients with closed epiphyses
* Prader-Willi syndrome, Turner syndrome or any other genetic or chromosomal anomaly
* Treatment with inhaled or systemic steroids
* BMI \<5th percentile or \>95th percentile
* Tanner 2 at clinical or biochemical examination by ultrasensitive LH and FSH

Primary outcomes:
measure: Primary Efficacy Outcome measurement
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Brooklyn
country: United States
facility: Maimonides Medical Center
state: New York
Study officials:
affiliation: Maimonides Medical Center
name: Svetlana Ten, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00920400: Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract
Official title: Value of Fecal Calprotectin in Upper Gastrointestinal Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peptic Esophagitis
Peptic Ulcer
Functional Dyspepsia
Irritable Bowel Syndrome
Inflammatory Bowel Diseases
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2009-06-15
Enrollment: 287
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 300 consecutive patients undergoing upper endoscopy at the Department of Gastroenterology \& Hepatology at the University Hospital Basel

Brief summary: Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious gastroenteritis. Elevated calprotectin levels can also be found in patients with lesion only in the upper gastrointestinal tract. However, the diagnostic value of calprotectin has never been tested in this setting. The aim of the study is therefore to determine the diagnostic value of fecal calprotectin in patients with diseases of the upper gastrointestinal tract.


Eligibility criteria: Inclusion Criteria:

* All patients referred for upper gastrointestinal endoscopy for any reason
* Older than 18 years

Exclusion Criteria:

* Patients who are not able to provide informed consent
* Patients who are not able to provide a stool sample

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Department of Gastroenterology & Hepatology
state: Basel-Stand
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Christoph Beglinger, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04780100: Distinguishing Acetabulum Cup Retroversion From Anteversion on Anteroposterior Radiographs After Total Hip Arthroplasty
Official title: Distinguishing Acetabulum Cup Retroversion From Anteversion on Anteroposterior Radiographs After Total Hip Arthroplasty
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Orthopedics
Lead sponsor: Taipei Medical University
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 20
Sex: ALL
Minimum age (years): 30
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from Shuang Ho Hospital

Brief summary: In this study, investigators will demonstrate and prove a ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion.

Detailed description: Total hip arthroplasty (THA) is considered to be the best and most reliable treatment of end-stage hip disorders with satisfactory long-term clinical outcomes. However,the incidence of postoperative dislocation ranges from 0.3% to 3% in primary THA. The most important risk factor is malpositioning of implant components. Generally, excessive anteversion and retroversion increase risk of anterior and posterior hip dislocation respectively. Several radiological methods have been proposed to measure anteversion of the acetabular cup on plain radiographs, but most of these methods cannot accurately distinguish cup retroversion from anteversion. In this study, investigators will demonstrate and prove a ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion.

Eligibility criteria: Inclusion Criteria:

* Patients undergone total hip arthroplasty
* Patients undergone total hip arthroplasty with more than two postoperative anteroposterior radiographs of pelvis
* Patients undergone total hip arthroplasty with postoperative pelvic CT

Exclusion Criteria:

* Patients with congenital pelvis abnormality or pelvic fracture history
* Patients with postoperative periprosthetic fracture(s)
* Patients with postoperative infection or implants loosening
* Patients undergone total hip arthroplasty without more than two postoperative anteroposterior radiographs of pelvis
* Patients undergone total hip arthroplasty without postoperative pelvic CT

Primary outcomes:
measure: A computerized ellipse method (Liaw's version) for measurement and detection of acetabulum cup retroversion.
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Taipei Medical University
name: Chen-Kun Liaw
role: STUDY_CHAIR
References: